The present study evaluated the antihyperglycemic, hepatoprotective, and hypolipidemic effects of F. racemosa bark powder and aqueous extract in streptozotocin-induced diabetic rats. Streptozotocin-induced diabetic rats (n = 6) were treated with F. racemosa Linn (Moraceae) bark powder (FRP) and aqueous extract (FRAE) for six weeks. Blood glucose was determined every 15 days using a portable glucometer. At the end of the study period, the rats were sacriÞ ced and levels of serum glucose, protein, total cholesterol, triglycerides, AST, ALT, TBARS, and glutathione were determined as indicators of antihyperglycemic, hypolipidemic, and hepatoprotective activities, as well as of antioxidant potential. TBARS and glutathione levels were determined in the liver and the kidneys also. Both the bark powder and aqueous extract of F. racemosa bark caused a signiÞ cant reduction (P ≤ 0.05) in blood glucose (54 and 66% respectively). A signiÞ cant reduction (P ≤ 0.05) was also observed in serum cholesterol and triglyceride levels to the control levels. The aqueous extract was more effective and caused a signiÞ cant reduction (P ≤ 0.05) in TBARS, AST, ALT levels compared to untreated diabetic rats. However, it did not reach control levels. A signiÞ cant increase in glutathione concentrations over the control levels was also observed in rats treated with F. racemosa bark. It is concluded that F. racemosa bark has a signiÞ cant hypolipidemic and hepatoprotective effect besides being a potent antihyperglycemic agent.
INTRODUCTION
Several members of the genus Ficus (Moraceae) are being used traditionally in a wide variety of ethnomedical remedies. One among them, Ficus racemosa Linn., syn. Ficus glomerata Roxb., commonly known as 'Gular', 'Umbar,' or 'Jagyadumbar,' [1, 2] is widely distributed all over India, northern Australia, and other parts of Asia. All parts of this plant are medicinally important in the traditional system of medicine in India and have been used extensively in biliary disorders, jaundice, dysentery, diabetes, diarrhea, and in inß ammatory conditions. [3] [4] [5] The stem bark of the tree is employed in the indigenous systems In view of the above knowledge, the present study was planned to explore the glucose-lowering, hepatoprotective, and hypolipidemic potential of F. racemosa bark powder and aqueous extract in streptozotocin-induced diabetic rats.
MATERIALS AND METHODS

Collection of plant material
Ficus racemosa Linn. stem bark was collected from Mukkadahally, Chamarajanagar district of Karnataka, India, and a voucher specimen was subsequently deposited at the herbarium of Department of Studies in Botany, University of Mysore, Mysore (BOT-001/2008).
Preparation of aqueous extract
The bark was cut into small pieces, spread over Þ lter sheets, and dried overnight in a vacuum oven at 50°C. The dried pieces were ground to a Þ ne powder in a dry grinder, passed through 60 mesh sieve (BS) and stored in an airtight container at 4°C until further use. A weighed quantity (100 g) of this powder was taken into a conical ß ask containing 800 mL distilled water and extracted using a temperature-controlled mechanical shaker at 70°C for 24 h. The extract was Þ ltered and freeze-dried (yield: 12% w/w).
Animals
Healthy adult male Wistar rats between eight and nine weeks of age and weighing 140-160 g were obtained from the Central animal house, Department of Zoology, University of Mysore. The rats were housed individually in metal cages, maintained under standard conditions (12 h light and 12 h dark cycles; 27±2°C; 45-60% humidity). The animals were fed a standard diet consisting of wheat ß our (62%), soy ß our (18%), sugar (7%), mineral mixture (2%), vitamin mixture (1%), and groundnut oil (1%) corresponding to 60% carbohydrates, 30% protein, 5% fat, and 5% Þ ber and were provided with food and water ad libitum. All animal procedures have been approved by the Animal Ethical Committee of the University of Mysore.
Experimental design and induction of diabetes
The rats were assigned to six groups (n = 6), control group: nondiabetic rats, FRP group: Ficus racemosa powder-treated diabetic rats, FRAE group: Ficus racemosa aqueous extract-treated diabetic rats, DC group: Untreated diabetic rats, GB group: Glibenclamide-treated diabetic rats (400 µg/day/kg body weight), [14] IN group: Insulin-treated diabetic rats (5 U/day/kg). [14] Diabetes was induced in the experimental groups by a single intramuscular injection of streptozotocin (55 mg/kg, Sigma Aldrich, India) dissolved in citrate buffer (0.1 M, pH 4.5) after 24 h of fasting. [15] Hyperglycemia was conÞ rmed by elevated blood glucose levels after 72 h and rats with fasting blood glucose > 250 mg/dL were selected for the study. The powder and aqueous extract were mixed at dose levels of 500 mg/kg body weight with the diets of the respective experimental groups. The animals were maintained for six weeks with the above treatment.
Assay of biochemical parameters
Blood glucose levels were estimated using a glucometer (Accu-chek, Roche Diagnostics, Germany) every 15 days. At the end of the study period, rats were decapitated, blood samples were collected by direct cardiac puncture, centrifuged at 2500 g for 20 min, and used for the assay of the following biochemical parameters using diagnostic kits from Agappe Diagnostics, India: [16] and glutathione by the method of Ellman. [17] TBARS and glutathione levels were also determined in serum.
Statistical analysis
The data was analyzed by ANOVA, followed by Tukey's multiple comparisons test for signiÞ cant differences using SPSS 14.0 computer software. Values were considered to be signiÞ cant at P ≤ 0.05.
RESULTS
Changes in blood glucose of various groups are presented in Figure 1 . FRP and FRAE caused a signiÞ cant reduction (P ≤ 0.05) of fasting blood glucose (54 and 66% respectively) but not to control levels. The antihyperglycemic effect of FRP and FRAE did not differ statistically (P ≤ 0.05) with the antihyperglycemic effect of FRAE being comparable to that of glibenclamide. As expected, the standard antidiabetic agents, insulin and glibenclamide, reduced the fasting blood glucose levels to the control levels. The percent reduction brought about by insulin and glibenclamide were 78 and 74% respectively.
Serum cholesterol and triglyceride levels were signiÞ cantly higher (P ≤ 0.05) in the DC group compared to those of the control group [ Table 1 ]. Administration of FRP and FRAE caused a highly signiÞ cant (P ≤ 0.01) reduction in serum cholesterol and triglyceride levels comparable to those of the control group. Similar observations were also found with respect to the IN-and GB-treated groups where serum cholesterol and triglyceride levels were decreased to control levels. The total protein concentration was signiÞ cantly lower (P ≤ 0.05) in the DC group compared to that in the control group. However, no signiÞ cant differences were observed in total protein concentrations of the FRP, FRAE, IN, and GB groups in comparison with that of the control group. STZ injection caused a highly signiÞ cant reduction (P ≤ 0.05) of serum albumin concentration in the DC group compared to the control group. However, although administration of FRP and FRAE signiÞ cantly restored albumin levels, control levels were not reached. Similar observations were seen in IN-and GB-treated groups.
The hepatoprotective activity of FRP and FRAE was assessed by measuring the activity of serum transaminases (AST and ALT). The results reveal that both FRP and FRAE caused a signiÞ cant reduction (P ≤ 0.05) in the activity of both ALT and AST compared to the activity found in untreated diabetic rats [ Table 1 ].
Treatment of diabetic rats with FRP and FRAE resulted in a signiÞ cant (P ≤ 0.05) improvement in the antioxidant status, as evident by low TBARS and higher GSH levels in the serum, liver, and kidneys. TBARS concentrations were signiÞ cantly higher (P ≤ 0.05) in the serum, liver and kidneys of untreated animals than of the control group. The concentrations of GSH were signiÞ cantly lower (P ≤ 0.05) in untreated diabetic rats as well as the FRP-treated rats compared to control group. The concentrations of GSH in the liver and kidneys of FRP-treated animals were comparable to that of those in the FRAE group. However, administration of FRP and FRAE resulted in a signiÞ cant increase (P ≤ 0.05) in GSH levels compared to control and untreated diabetic rats [ Table 2 ].
DISCUSSION
Streptozotocin (STZ) is widely used to induce diabetes in experimental animals. As STZ is a nitric oxide (NO) donor and NO was found to bring about the destruction of pancreatic islet cells, NO has been proposed to contribute to STZ-induced DNA damage. [18, 19] STZ was also found to generate reactive oxygen species which contribute to DNA fragmentation and evoke deleterious changes in the cells. [20, 21] It has been suggested that some inhibitors of polyADP-ribosylation may also exert a protective effect due to their hydroxyl radical-scavenging properties. [22] The present investigation studied the hypoglycemic and hypolipidemic potential as well as the ability of F. racemosa to counteract free radicals in STZ-induced diabetic rats.
The hypoglycemic effect of F. racemosa can be attributed to the presence of leucocyanidin-3-O-β-D-glucopyrancoside, l e u c o p e l a r g o n i d i n -3 -O -β -D -g l u c o p y r a n o s i d e, leucopelargonidin-3-O-α-L-rhamnopyranoside, [23] all of which are known to reduce hyperglycemia. These compounds are also isolated from Ficus bengalensis and the leucopelargonidin derivative isolated from Ficus bengalensis has been shown to decrease fasting blood sugar levels at a dosage level of 100 mg/kg/day in diabetic rats to 34% of the levels in untreated diabetic rats. [24, 25] The levels of serum lipids are usually elevated in diabetes mellitus and such an elevation represents a risk factor for coronary heart disease. This abnormally high level of serum lipids is mainly due to the uninhibited actions of lipolytic hormones on the fat depots; thus, hypercholesterolemia and hypertriglyceridemia are known to occur in STZinduced diabetic rats. Under normal circumstances, insulin activates the enzyme lipoprotein lipase, which hydrolyzes triglycerides. However, lipoprotein lipase is not activated in conditions of insulin deficiency, thus resulting in hypertriglyceridemia. [28] The observed hypocholesterolemic and hypotriglyceridemic effects of F. racemosa bark can therefore be attributed to the activation of the enzyme, lipoprotein lipase.
A number of enzymes are synthesized by the liver and levels of some of these enzymes are commonly measured in the bloodstream to assess liver function. The reduction of AST and ALT caused by both FRP and FRAE reß ects the hepatoprotective effect of F. racemosa bark as levels of transaminases, often referred to as AST and ALT, are found to be elevated as a result of hepatic damage/injury. [28] Similar observations are reported by Subhash et al. where a petroleum ether extract of F. racemosa leaf caused a highly signiÞ cant reduction of AST and ALT in rats treated with carbon tetrachloride (CCL 4 ). [6] The low TBARS and higher GSH levels in the serum, kidney, and liver of F. racemosa-treated groups represent its antioxidant potential. As the chemical composition and medicinal uses of F. racemosa have been widely reported, the observed hepatoprotective and antioxidant effects could be attributed to the presence of the various phytoconstituents including tannins, kaempferol, rutin, bergapten, psoralenes, ß avonoids, Þ cusin, coumarin, and phenolic glycosides [26] that are reported to act as strong antioxidants and antiinß ammatory agents. [7] CONCLUSION From the results of the present study, it can be concluded that F. racemosa bark is a potent antihyperglycemic, hypolipidemic, and hepatoprotective agent. Further, the aqueous extract was more effective than the bark powder, indicating the role of water-soluble phytoconstituents rather than the plant Þ ber for the observed biological effects. The biological efÞ cacy of F. racemosa bark may be even higher after the isolation and puriÞ cation of the compound(s). Further studies in this direction are currently in progress.
